Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies
Gynecol Oncol
.
2022 Apr;165(1):11-13.
doi: 10.1016/j.ygyno.2022.02.003.
Epub 2022 Feb 12.
Authors
Jhalak Dholakia
1
,
Margaret I Liang
1
,
Emeline M Aviki
2
Affiliations
1
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA.
2
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: avikie@mskcc.org.
PMID:
35168821
DOI:
10.1016/j.ygyno.2022.02.003
No abstract available
Publication types
Editorial
MeSH terms
Costs and Cost Analysis
Female
Genital Neoplasms, Female* / pathology
Genital Neoplasms, Female* / therapy
Humans
Medical Oncology